BTK Inhibitor CC-292

An orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, CC-292 targets and covalently binds to BTK, thereby preventing its activity. By irreversibly inhibiting BTK, administration of this agent may lead to an inhibition of B cell receptor (BCR) signaling and may inhibit cell proliferation of B-cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival. (NCI Thesaurus)

YOU MAY ALSO LIKE

BTK Inhibitor ACP-196

An orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and…

BTK Gene

This gene is involved in both signaling and B-cell development.

BTG2 wt Allele

Human BTG2 wild-type allele is located in the vicinity of 1q32 and is approximately 4 kb in length. This allele, which encodes…

BTG2 Gene

This gene is involved in the regulation of the G1/S transition of the cell cycle.

BTG1 wt Allele

Human BTG1 wild-type allele is located in the vicinity of 12q22 and is approximately 3 kb in length. This allele, which encodes…

BTG1 Gene

This gene is involved in the regulation of cell proliferation.